Skye Bioscience Inc Ordinary Shares SKYE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SKYE is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $12.68
- Day Range
- $12.15–13.44
- 52-Week Range
- $1.44–19.41
- Bid/Ask
- $4.93 / $18.88
- Market Cap
- $343.83 Mil
- Volume/Avg
- 46,176 / 51,725
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 11
- Website
- https://www.skyebioscience.com
Valuation
|
Metric
|
SKYE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SKYE
Financial Strength
|
Metric
|
SKYE
|
|---|---|
Quick Ratio | 5.28 |
Current Ratio | 5.99 |
Interest Coverage | −27.20 |
Quick Ratio
SKYE
Profitability
|
Metric
|
SKYE
|
|---|---|
Return on Assets (Normalized) | −9.08% |
Return on Equity (Normalized) | −17.81% |
Return on Invested Capital (Normalized) | −10.56% |
Return on Assets
SKYE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dlvjvqmpnb | Qzzgc | $593.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Shhmzjjpc | Vwgmf | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rnbpbkx | Jrxvg | $106.7 Bil | |
MRNA
| Moderna Inc | Twxdmfvj | Xtx | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Mzcztdlp | Hsdpt | $22.4 Bil | |
ARGX
| argenx SE ADR | Bcvzxmy | Zvy | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mhsrwbn | Xlfnc | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jybpybsf | Wtcmsh | $14.6 Bil | |
INCY
| Incyte Corp | Czcwsbzz | Kzvyh | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yjzdwjvxm | Nrzmvfz | $12.6 Bil |